Adam Feuerstein, biotech reporter at Stat News, stated in a post to X: “Cantor is escorting $MLTX management on a ‘non-deal roadshow’ with investors on July 7, 8 and 10 in NYC and Boston. There is no imminent acquisition.” Earlier this month, the MoonLake Immunotherapeutics (MLTX) takeover thesis reemerged after the Financial Times reported Merck (MRK) expressed interested in acquiring MoonLake and submitted a non-binding offer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics Elects Directors at AGM
- MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating
- MoonLake takeover thesis reemerges after FT report, says Citi
- Closing Bell Movers: Credo Technology jumps 11% on earnings
- Merck held talks to buy MoonLake for over $3B, FT reports